CBD: the new tool to kick the smoking habit?
NCT ID NCT05445804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily oral dose of cannabidiol (CBD) can help people stop smoking tobacco. Fifty adults who smoke more than 10 cigarettes a day and want to quit will take CBD during several practice quit attempts. The goal is to see if CBD increases short-term abstinence and understand how it changes smoking behavior.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2022
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Have provided written informed consent 2. Be between the ages of 18 and 65 3. Report use of \> 10 cigarettes per day for \> 1 year with smoking status verified by either a positive breath carbon monoxide test (\>8ppm) or urine cotinine test (\>200ng/mL) at screening 4. Report interest in quitting tobacco in the next two months 5. Are willing to engage in a series of practice quit attempts as part of the study. 6. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests as determined by a licensed medical professional. 7. For women of children bearing potential and men with female partners of child-bearing potential, must be willing to use an effective form of contraception during the study and for at least 30 days after the last study drug administration. Acceptable forms of contraception include: double barrier contraception or a combination of a barrier contraception and a hormonal implant, injectable, combined oral contraceptive, or a male partner who has had a vasectomy; intrauterine device or tubal ligation. Exclusion Criteria: 1. Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders 2. Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation 3. Test positive for drugs of abuse (except nicotine) and/or breath alcohol test at study admission 4. Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity. 5. Have a lifetime history of suicidal behavior (i.e. past suicide attempt), or current suicidal behavior or ideation as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 6. Are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding. 7. Use of an over the counter, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study results or the safety of the participant 8. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days (or 5 half-lives for that specific drug) of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the participant. This includes any medication metabolized via CYP2D6, CYP2C9, CYP2B10, or which induce/inhibit CYP3A4 enzymes. 9. Have a history of clinically significant cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina). 10. Have elevated serum liver transaminase (AST or ALT) above 2 x upper limit of normal, or elevated bilirubin above 1.5 x upper limit of normal. 11. Are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation. \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tobacco dependence are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Johns Hopkins Behavioral Pharmacology Research Unit
RECRUITINGBaltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can a WhatsApp message help smokers quit?
- Can a single talk session help cancer patients quit smoking?
- One extra therapy session may keep cancer patients off cigarettes
- Can a brain scan tailor TMS to quiet cigarette cravings?
- Practice quitting: a new way to help smokers who Aren't ready to stop?